Skip Navigation

Nucleic Acids Research 2004 32(18):5499-5511; doi:10.1093/nar/gkh880
This Article
Right arrow Full Text Freely available
Right arrow Print PDF (550K) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Commercial Re-use Guidelines
for Open Access NAR Content
Google Scholar
Right arrow Articles by Lee, K.-H.
Right arrow Articles by Chun, Y.-S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, K.-H.
Right arrow Articles by Chun, Y.-S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published online 12 October 2004

Nucleic Acids Research, Vol. 32 No. 18 © Oxford University Press 2004; all rights reserved

Non-hypoxic transcriptional activation of the aryl hydrocarbon receptor nuclear translocator in concert with a novel hypoxia-inducible factor-1alpha isoform

Kyoung-Hwa Lee, Jong-Wan Park and Yang-Sook Chun1,2,*

Department of Pharmacology, 1 Department of Physiology and 2 Cancer Research Institute, Seoul National University College of Medicine, 28 Yongon-dong, Chongno-gu, Seoul 110-799, Korea

* To whom correspondence should be addressed. Tel: +82 2 36687937; Fax: +82 2 7457996; Email: chunys{at}snu.ac.kr

Received July 15, 2004; Revised and Accepted September 20, 2004

Aryl hydrocarbon receptor nuclear translocator (ARNT) belongs to the basic helix–loop–helix Per-Arnt-Sim (bHLH PAS) protein which dimerizes with other PAS proteins. Although it has a transactivation domain (TAD), ARNT functions as an assistant partner of main factors, such as aryl hydrocarbon receptor and hypoxia-inducible factors, rather than acting as a straightforward transcription factor. However, ARNT may function as an active transcription factor using its TAD either in association with itself, single-minded protein 1, or trachealess protein. In the present study, we identified a novel ARNT partner, a HIF-1{alpha} variant, which is ubiquitously expressed in human tissues and cancer cell lines. The HIF-1{alpha} variant, designated HIF-1{alpha}417, bound to ARNT and, moreover, stimulated the transcription of the erythropoietin enhancer reporter gene. This stimulation was markedly augmented by ARNT but not by the ARNT603 mutant lacking the TAD. Thus, augmentation by ARNT suggests that ARNT determined the transcriptional activity. HIF-1{alpha}417 was found to be associated with ARNT and to bind to the hypoxia response element containing the E-box core. Moreover, HIF-1{alpha}417 promoted the nuclear translocation of ARNT, and conversely ARNT stabilized HIF-1{alpha}417. Taken together, our results suggest that HIF-1{alpha}417 is a novel partner that is required for transcription activity of ARNT.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
H. Choi, Y.-S. Chun, S.-W. Kim, M.-S. Kim, and J.-W. Park
Curcumin Inhibits Hypoxia-Inducible Factor-1 by Degrading Aryl Hydrocarbon Receptor Nuclear Translocator: A Mechanism of Tumor Growth Inhibition
Mol. Pharmacol., November 1, 2006; 70(5): 1664 - 1671.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
J. Fandrey, T. A. Gorr, and M. Gassmann
Regulating cellular oxygen sensing by hydroxylation
Cardiovasc Res, September 1, 2006; 71(4): 642 - 651.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
B. Kaur, F. W. Khwaja, E. A. Severson, S. L. Matheny, D. J. Brat, and E. G. Van Meir
Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis
Neuro-oncol, April 1, 2005; 7(2): 134 - 153.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.